NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ...
The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...
According to Benzinga Pro, Biogen's peer group average for short interest as a percentage of float is 5.09%, which means the company has less short interest than most of its peers. Did you know that ...
Biogen (BIIB) announced the appointment of Adam Feire, Ph.D., as Head of Business Development and External Innovation. Feire reports to Adam ...
This was the stock's second consecutive day of losses.
1d
We recently published a list of Jim Cramer Discussed These 10 NASDAQ 100 Stocks Recently. In this article, we are going to ...
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first ...
Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...
The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...
Risk for venous thromboembolism during pregnancy increased significantly from 2009 to 2019, with an average annual percent ...
Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...
Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback